Calumet (CLMT) has drawn investor attention after reporting first quarter 2026 results. The company posted sales of US$1,029.7 million and a wider net loss of US$317 million, partly linked to operational disruptions.

Calumet's first quarter loss has not derailed momentum entirely, with a 90 day share price return of 16.81% and a year to date share price return of 68.13%, while the 1 year total shareholder return is 132.30%. This suggests investors are still reassessing the balance between renewables growth potential and operational risk.

If this kind of turnaround story has your attention, it can be useful to compare it with other companies and see what stands out in a 20 top founder-led companies

With the stock up strongly over the past year and trading about 13% below analyst targets, the key question is whether the current price already reflects Calumet's renewables ambitions or whether the recent volatility has created a potential opportunity for investors.

Most Popular Narrative: 40.2% Overvalued

At a last close of $32.87 versus a narrative fair value of $23.45, the most followed framework points to a rich valuation and leans heavily on renewable fuels ramping up.

The MaxSAF 150 project is on track to start up in the first half of 2026, enabling Calumet to produce 120-150 million annual gallons of sustainable aviation fuel (SAF) at relatively low capital costs, capturing premiums of $1-$2/gallon over renewable diesel and tapping into surging mandated and voluntary SAF demand globally; this is likely to drive material step-up in revenues and EBITDA margin expansion once operational.

Want to see what kind of revenue lift, margin shift and future earnings multiple this story leans on, and how those assumptions tie back to that fair value tag? Result: Fair Value of $23.45 (OVERVALUED)

However, this hinges on regulators staying supportive and debt markets remaining accessible. Any policy reversal or funding setback could quickly challenge that upbeat fair value story.

Another Angle on Valuation

The narrative fair value of $23.45 suggests Calumet is richly priced, but the P/S story is less clear cut. At 0.7x sales, the stock trades well below the US Oil and Gas industry at 2.1x, yet above peer levels around 0.2x and in line with a fair ratio of 0.7x. That mix of discount and premium raises a simple question for you: is the market underestimating Calumet's risk, or already giving full credit for its renewables plans?

To see how that P/S gap versus peers, industry and the fair ratio translates into practical valuation risk, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation, risks and rewards, you may want to look at the full picture yourself, act while sentiment is fresh, and weigh up the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Calumet has sharpened your focus, do not stop here. Broaden your watchlist with fresh ideas that balance quality, income and risk control.

• Spot potential bargains early by scanning 53 high quality undervalued stocks with strong fundamentals that may not yet be fully appreciated by the market.
• Lock in portfolio income by reviewing 10 dividend fortresses that pair higher yields with a focus on resilience.
• Dial down risk by checking 66 resilient stocks with low risk scores that score well on balance sheet strength and volatility.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.